Why are cytokines targeted for biological therapy in IBD?
Saruta
Masayuki
M
Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, California, USA.
Papadakis
Konstantinos A
KA
D001688:Biological Products / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D018928:Immunity, Mucosal; D007167:Immunotherapy; D015212:Inflammatory Bowel Diseases / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*
D001688:Biological Products; D016207:Cytokines